CLINICAL TRIALS PROFILE FOR TYVASO
✉ Email this page to a colleague
All Clinical Trials for TYVASO
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00147199 ↗ | Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH) | Completed | United Therapeutics | Phase 3 | 2005-06-01 | This is a double-blind placebo-controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension. The primary outcome is the change in 6-minute walk distance from baseline to week 12. |
NCT00741819 ↗ | Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects | Completed | United Therapeutics | Phase 4 | 2008-09-01 | This is a 24-month, multi-center, prospective, open-label, safety evaluation in PAH subjects following transition from a stable dose of inhaled iloprost (Ventavis). Subjects are to be evaluated for safety throughout the course of the study while secondary assessments will be conducted at Baseline, Week 6, Week 12, and Months 6, 12, 18 and 24 following initiation of treprostinil sodium. |
NCT01266265 ↗ | Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies | Completed | United Therapeutics | 2010-12-01 | A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies | |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TYVASO
Condition Name
Clinical Trial Locations for TYVASO
Trials by Country
Clinical Trial Progress for TYVASO
Clinical Trial Phase
Clinical Trial Sponsors for TYVASO
Sponsor Name